Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis

Ballooning degeneration of hepatocytes is a major distinguishing histological feature of non-alcoholic steatosis (NASH) progression that can lead to cirrhosis and hepatocellular carcinoma (HCC). In this study, we evaluated the effect of the selective PPARα modulator (SPPARMα) pemafibrate (Pema) and sodium-glucose cotransporter 2 (SGLT2) inhibitor tofogliflozin (Tofo) combination treatment on pathological progression in the liver of a mouse model of NASH (STAM) at two time points (onset of NASH progression and HCC survival). At both time points, the Pema and Tofo combination treatment significantly alleviated hyperglycemia and hypertriglyceridemia. The combination treatment significantly reduced ballooning degeneration of hepatocytes. RNA-seq analysis suggested that Pema and Tofo combination treatment resulted in an increase in glyceroneogenesis, triglyceride (TG) uptake, lipolysis and liberated fatty acids re-esterification into TG, lipid droplet (LD) formation, and Cidea/Cidec ratio along with an increased number and reduced size and area of LDs. In addition, combination treatment reduced expression levels of endoplasmic reticulum stress-related genes (Ire1a, Grp78, Xbp1, and Phlda3). Pema and Tofo treatment significantly improved survival rates and reduced the number of tumors in the liver compared to the NASH control group. These results suggest that SPPARMα and SGLT2 inhibitor combination therapy has therapeutic potential to prevent NASH-HCC progression.

[1]  R. Correa-Rotter,et al.  Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review , 2021, Frontiers in Medicine.

[2]  R. Carr,et al.  A new perspective on NAFLD: focusing on lipid droplets. , 2021, Journal of hepatology.

[3]  Natalie Porat-Shliom,et al.  Liver Zonation – Revisiting Old Questions With New Technologies , 2021, Frontiers in Physiology.

[4]  J. B. Steinman,et al.  Zonation in NASH – A key paradigm for understanding pathophysiology and clinical outcomes , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[5]  E. Harris,et al.  Pathophysiological Communication between Hepatocytes and Non-Parenchymal Cells in Liver Injury from NAFLD to Liver Fibrosis. , 2021, Advanced drug delivery reviews.

[6]  A. Enomoto,et al.  The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  P. Gentileschi,et al.  Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome , 2021, Microbiome.

[8]  H. Randeva,et al.  Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives , 2021, Current Obesity Reports.

[9]  Ja Hyun Koo,et al.  Signaling Nodes Associated with Endoplasmic Reticulum Stress during NAFLD Progression , 2021, Biomolecules.

[10]  A. Grefhorst,et al.  The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease , 2021, Frontiers in Endocrinology.

[11]  J. Lundeberg,et al.  Spatial Transcriptomics to define transcriptional patterns of zonation and structural components in the mouse liver , 2020, Nature Communications.

[12]  R. Ritchie,et al.  Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments , 2020, Frontiers in Pharmacology.

[13]  D. Mashek.  Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD , 2020, Molecular metabolism.

[14]  H. Kang,et al.  Holistic Characterization of Single Hepatocyte Transcriptome Responses to High Fat Diet. , 2020, American journal of physiology. Endocrinology and metabolism.

[15]  Xinran Liu,et al.  FIT2 is an acyl–coenzyme A diphosphatase crucial for endoplasmic reticulum homeostasis , 2020, The Journal of cell biology.

[16]  H. D. de Valk,et al.  Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis , 2020, The Journal of clinical endocrinology and metabolism.

[17]  R. Ohki,et al.  p53-PHLDA3-Akt Network: The Key Regulators of Neuroendocrine Tumorigenesis , 2020, International journal of molecular sciences.

[18]  H. Aburatani,et al.  Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content , 2020, Scientific Reports.

[19]  S. Ikramuddin,et al.  Nonalcoholic Steatohepatitis: A Review. , 2020, JAMA.

[20]  V. Wong,et al.  Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials. , 2020, Journal of hepatology.

[21]  N. Bhala,et al.  Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[22]  H. Malhi,et al.  Pathogenesis of Nonalcoholic Steatohepatitis: An Overview , 2020, Hepatology communications.

[23]  T. Kodama,et al.  Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate , 2019, International journal of molecular sciences.

[24]  Jiandie D. Lin,et al.  Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis. , 2019, Molecular cell.

[25]  James E. Cox,et al.  Targeting a ceramide double bond improves insulin resistance and hepatic steatosis , 2019, Science.

[26]  M. Blüher,et al.  Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis , 2019, EMBO molecular medicine.

[27]  A. Iannelli,et al.  The Differential Expression of Cide Family Members is Associated with Nafld Progression from Steatosis to Steatohepatitis , 2019, Scientific Reports.

[28]  J. Olzmann,et al.  Dynamics and functions of lipid droplets , 2018, Nature Reviews Molecular Cell Biology.

[29]  J. Hampe,et al.  Epigenomic map of human liver reveals principles of zonated morphogenic and metabolic control , 2018, Nature Communications.

[30]  P. Gentileschi,et al.  Molecular Phenomics and Metagenomics of Hepatic Steatosis in Non-Diabetic Obese Women , 2018, Nature Medicine.

[31]  Wataru Yano,et al.  Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction , 2018, Physiological reports.

[32]  J. Fruchart.  Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia , 2017, Cardiovascular Diabetology.

[33]  Li Xu,et al.  Control of lipid droplet fusion and growth by CIDE family proteins. , 2017, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[34]  Robert V Farese,et al.  Lipid Droplet Biogenesis. , 2017, Annual review of cell and developmental biology.

[35]  Robert V Farese,et al.  Triglyceride Synthesis by DGAT1 Protects Adipocytes from Lipid-Induced ER Stress during Lipolysis. , 2017, Cell Metabolism.

[36]  Albert Gough,et al.  Pre-clinical and clinical investigations of metabolic zonation in liver diseases: The potential of microphysiology systems , 2017, Experimental biology and medicine.

[37]  Shelly C. Lu,et al.  Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. , 2017, Gastroenterology.

[38]  H. Shimano,et al.  Selective peroxisome proliferator‐activated receptor‐α modulator K‐877 efficiently activates the peroxisome proliferator‐activated receptor‐α pathway and improves lipid metabolism in mice , 2017, Journal of diabetes investigation.

[39]  T. Kietzmann.  Metabolic zonation of the liver: The oxygen gradient revisited , 2017, Redox biology.

[40]  Mathias Beller,et al.  The why, when and how of lipid droplet diversity , 2017, Journal of Cell Science.

[41]  I. Amit,et al.  Single-cell spatial reconstruction reveals global division of labor in the mammalian liver , 2016, Nature.

[42]  B. Neuschwander‐Tetri,et al.  In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. , 2016, Gastroenterology.

[43]  T. Kadowaki,et al.  Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. , 2016, Endocrinology.

[44]  P. Bedossa.  Histological Assessment of NAFLD , 2016, Digestive Diseases and Sciences.

[45]  B. Staels,et al.  Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. , 2016, Annual review of physiology.

[46]  A. Nakajima,et al.  The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice , 2016, PloS one.

[47]  T. Kodama,et al.  Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver. , 2015, Journal of atherosclerosis and thrombosis.

[48]  Ja Hyun Koo,et al.  PHLDA3 overexpression in hepatocytes by endoplasmic reticulum stress via IRE1–Xbp1s pathway expedites liver injury , 2015, Gut.

[49]  H. Aburatani,et al.  PPARβ/δ activation of CD300a controls intestinal immunity , 2014, Scientific Reports.

[50]  K. Irvine,et al.  The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease , 2014, Hepatology.

[51]  P. Misra,et al.  Peroxisome proliferator-activated receptor-α activation and excess energy burning in hepatocarcinogenesis. , 2014, Biochimie.

[52]  J. Fruchart,et al.  Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists , 2013, Cardiovascular Diabetology.

[53]  S. Watkins,et al.  The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. , 2012, Cell metabolism.

[54]  E. Ferrannini,et al.  SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects , 2012, Nature Reviews Endocrinology.

[55]  Randal J. Kaufman,et al.  Endoplasmic reticulum stress in liver disease. , 2011, Journal of hepatology.

[56]  R. Austin,et al.  Endoplasmic reticulum stress and lipid dysregulation , 2011, Expert Reviews in Molecular Medicine.

[57]  J. Fruchart.  Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. , 2009, Atherosclerosis.

[58]  B. Neuschwander‐Tetri,et al.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD—Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network , 2009, Hepatology.

[59]  P. Iynedjian.  Molecular Physiology of Mammalian Glucokinase , 2008, Cellular and Molecular Life Sciences.

[60]  F. Gonzalez,et al.  PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. , 2008, Toxicology.

[61]  B. Staels,et al.  Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. , 2007, Bioorganic & medicinal chemistry letters.

[62]  Michael Roden,et al.  Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[63]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[64]  I. Shimomura,et al.  Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[65]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[66]  D. Cook,et al.  Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes. , 2005, American journal of physiology. Endocrinology and metabolism.

[67]  Johan Auwerx,et al.  Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[68]  G. Jacquemin.  [Nonalcoholic steatohepatitis: a review]. , 2003, Revue medicale de Liege.

[69]  Michael Roden,et al.  NAFLD and diabetes mellitus , 2017, Nature Reviews Gastroenterology &Hepatology.

[70]  A. Suzuki,et al.  Nonalcoholic Steatohepatitis. , 2017, Annual review of medicine.

[71]  A. Scheen.  Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus , 2014, Drugs.

[72]  Pingchaun Li,et al.  Ursolic acid induces ER stress response to activate ASK1-JNK signaling and induce apoptosis in human bladder cancer T24 cells. , 2013, Cellular signalling.

[73]  Å. Lernmark,et al.  Hepatic steatosis in type 1 diabetes. , 2011, The review of diabetic studies : RDS.

[74]  J. Auwerx,et al.  Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. , 2003, Proceedings of the National Academy of Sciences of the United States of America.